Liquidia falls 50% after losing two patent claims to United Therapeutics, which rises 14%

Liquidia shares fell about 50% on Wednesday, and United Therapeutics rose about 14%, after a federal court in Delaware ruled that Liquidia's inhaled drug Yutrepia infringes two claims of a United Therapeutics patent. Liquidia was at $35.48 at 2:59 p.m. ET, against a $70.69 close on Tuesday, and United Therapeutics was at $549.15, up from $481.47, according to Nasdaq data.

What the court actually decided

According to Liquidia's own statement, the court found claims 1 and 14 of the '327 patent valid and infringed. Those claims cover treating pulmonary hypertension associated with interstitial lung disease (PH-ILD) with inhaled treprostinil, including dry-powder versions like Yutrepia. The other four claims United Therapeutics asserted were found invalid.

No remedy has been set. The court gave the two sides one week to submit a proposed form of judgment. Liquidia said the outcome could range from removing the PH-ILD indication from Yutrepia's label to "a broader restriction on product availability," and noted that United Therapeutics asked the court in post-trial briefs for an injunction that would limit Yutrepia's availability. Liquidia said it plans to appeal and intends to file with the FDA to remove PH-ILD from the label. CEO Roger Jeffs said the company "respectfully disagree[s]" with the ruling on the two claims.

The thing the headline gets wrong

"Liquidia loses patent case" is how most headlines read, and that overstates what happened Wednesday. Liquidia lost on two claims, won on four, and still sells Yutrepia for pulmonary arterial hypertension (PAH), which the ruled-on claims do not cover. A 50% drop on a day with no remedy yet means the market is pricing a real chance the court goes past a label change. That question gets answered in the next few weeks, not today.

The number behind the number

Yutrepia is almost all of Liquidia's business. Its second-quarter results, filed with the SEC in August, showed $170.4 million of Yutrepia net sales, up 31% from the first quarter, net income of $74.7 million and $284.2 million in cash. The company did not break out how much of that came from PH-ILD patients against PAH patients, and that split is the figure investors need most right now.

The market value math, using the share counts on each company's latest 10-Q cover page (89.5 million for Liquidia, 42.9 million for United Therapeutics):

The two moves are close to mirror images. At Wednesday's price, Liquidia is worth about $3.2 billion, roughly 4.7 times its second-quarter Yutrepia sales run rate of about $682 million a year. United Therapeutics, which brought the case, also sells treprostinil-based treatments. That is why investors read a restriction on Yutrepia as a gain for United Therapeutics.

What traders are watching

• The proposed judgments, due to the court within a week, and whether the judge grants the injunction United Therapeutics has asked for.
• Liquidia's FDA filing to drop PH-ILD from the label, and the timing of its appeal.
• Liquidia's third-quarter report, which will show how Yutrepia sales held up before the ruling.

Filings for both companies are on SEC EDGAR.

Sources: Liquidia press release via GlobeNewswire; Liquidia Q2 2026 results, SEC filing; United Therapeutics 10-Q on SEC EDGAR; Nasdaq. Prices are intraday and will change. This is market information, not investment advice.